肿瘤药学2025，Vol.15Issue(1)：46-52,7.DOI:10.3969/j.issn.2095-1264.2025.01.06
抗血管生成药物在复发性卵巢癌中的研究进展
Research progress of anti-angiogenic drugs in recurrent ovarian cancer
摘要
Abstract
Ovarian cancer ranks first in recurrence rate and mortality among gynecological malignant tumors.The pro-gression of malignant tumors relies on sufficient blood supply,driving the development of targeted therapies such as anti-angiogenic treatments to improve patient survival.This review summarizes the classification,mechanisms of action,adverse effects,and recent advances in clinical trials of anti-angiogenic agents for recurrent ovarian cancer.关键词
复发性卵巢癌/抗血管生成药物/贝伐珠单抗/酪氨酸激酶抑制剂Key words
Recurrent ovarian cancer/Anti-angiogenic drug/Bevacizumab/Tyrosine kinase inhibitors分类
临床医学引用本文复制引用
林淼,王瑞淇,张颐..抗血管生成药物在复发性卵巢癌中的研究进展[J].肿瘤药学,2025,15(1):46-52,7.基金项目
辽宁省应用基础研究计划(2022JH2/101300039). （2022JH2/101300039）
